托珠单抗 T9911

Product Introduction
Bioactivity


英文名: Tocilizumab

描述: Tocilizumab 是抗人白细胞介素-6 受体 (IL-6R) 的中和抗体，能够阻碍 IL-6 与 IL-6R 的结合，进而抑制经典和反式信号。它可用于研究类风湿性关节炎，对重症 COVID-19 冠状病毒病方面的研究具有显著效果。

细胞实验: Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function. Concentrations: 5 μg/ml. Incubation Time: 72 h. Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis. Cells:HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)

存储条件: store at -20°C

关键字: COVID-19 | IL-6R | Anti-Human IL6R, Humanized Antibody | rheumatoid | respiratory failure | antibody | Interleukin Related | coronavirus disease | arthritis | inhibit | Tocilizumab | dyspnoea | Neutralizing | Inhibitor

相关产品: Oxelumab | RCGD423 | Sodium Thiocyanate | Deucravacitinib | Ginsenoside Rh1 | Methylthiouracil | Kansuinine A | Talacotuzumab | Ossirene | Pectolinarin

托珠单抗 T9911信息由TargetMol中国为您提供，如您想了解更多关于托珠单抗 T9911报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途